Osta Biotechnologies Inc  

(Public, CVE:OBI)   Watch this stock  
Find more results for OBI
- Close
CVE data delayed by 15 mins - Disclaimer
Currency in
Range     -
52 week     -
Open     -
Vol / Avg. 0.00/0.00
Mkt cap 233,900.00
P/E     -
Div/yield     -
EPS -0.01
Shares     -
Beta     -
Inst. own     -

Key stats and ratios

Q3 (Sep '11) 2010
Net profit margin -42086.67% -13423.12%
Operating margin -42090.00% -13422.84%
EBITD margin - -13051.81%
Return on average assets -215.19% -91.09%
Return on average equity -576.34% -202.22%
CDP Score - -


179 Choquette Street
+1-514-6902919 (Phone)
+1-514-7275229 (Fax)

Website links


Osta Biotechnologies Inc. is a biopharmaceutical company. Its principal business is to carry out research and development work for the development of therapeutic products specific to cancer, Alzheimer’s disease, X-linked hypophosphatemia (XLH) and osteoporosis. The Company is a life sciences company focused on the development of therapeutic products for Cancer and Alzheimer's disease. Its wholly owned subsidiary includes Osta Biopharma Inc. (Osta). As of December 31, 2010, it did not have any products that are at the commercialization stage.

Officers and directors

Ajay Gupta Chairman of the Board, Chief Executive Officer
Andrew Karaplis President, Chief Scientific Officer, Director
William Waks CPA Chief Financial Officer
Age: 53
Michael Munzar M.D. Director
Age: 50
Leontis Teryazos Independent Director
Age: 61